1. A Process the Sponsor Does Not Control
Every one of the 260 sites in this program must be approved by an institutional review board before a single participant is screened. That review is conducted by a body that is independent of the sponsor by design, meets on its own schedule, and cannot be influenced, accelerated or appealed.
| Position | |
|---|---|
| Sites requiring ethics approval | 260 — every one |
| Approvals held at the status date | 231 |
| Weighted median time to approval | 5.8 weeks |
| Allowed in the activation plan | 5 weeks (weeks 9–14 of an 18-week sequence) |
| Sponsor levers that actually work | 3 of 6 |
A board a sponsor could hurry is a board a sponsor could pressure, and the entire protection it offers participants rests on it being neither. Every frustration in this document follows from that, and none of it is a defect to be engineered away.
What a program can do is stop treating the review as a delay and start treating it as a fixed input with a knowable schedule. Boards publish their meeting calendars and their submission cut-offs. A program that plans against those dates loses far less time than one that submits when it happens to be ready.
2. Central or Local — and What It Costs
| Review route | Sites | Share | Median to approval | Why |
|---|---|---|---|---|
| Central IRB | 178 | 68% | 4.5 wks | A single commercial board reviewing on behalf of multiple sites. Faster, consistent, and the default for sites whose institution permits it. |
| Local institutional IRB | 71 | 27% | 9.0 wks | ⚠ Academic medical centers that require their own board to review, typically meeting monthly with a submission deadline two weeks before. A single missed deadline costs six weeks, not one. |
| Local with central acceptance | 11 | 4% | 6.0 wks | Institutions that accept the central review but require a local administrative sign-off. Cheaper than a full local review and slower than none. |
| Weighted median | 260 | 100% | 5.8 wks | Against 5 weeks allowed in the activation plan. |
These are academic medical centers whose institutions do not permit central review. Their boards typically meet monthly, with a submission cut-off around two weeks before the meeting. Missing that cut-off by one day does not cost a day. It costs six weeks, because the next opportunity is the next meeting.
That is the mechanism behind the single most useful operational rule in this plan: the deadline is the cut-off, not the meeting.
The strategic decision was to use the central board wherever an institution permits it, which covers 178 sites. That is not a cost decision — a central board is not cheaper — it is a schedule decision, and it halves the median. The 71 sites that cannot use it were selected anyway, because ⚠ academic medical centers that require their own board to review, typically meeting monthly with a submission deadline two weeks before are also where much of the eligible population is.
3. Ethics Review Inside the Activation Sequence
The activation plan allows 5 weeks from IRB submission to approval. The weighted median across the network is 5.8.
| Weeks | Reading | |
|---|---|---|
| Planned activation, end to end | 18 | The Gate 4 assumption |
| Actual activation, running | 22 | 4 weeks over, and the origin of the enrolment shortfall |
| Allowed for ethics review | 5 | Weeks 9 to 14 of the sequence |
| Actual weighted ethics median | 5.8 | 0.8 weeks over — roughly 20% of the total overrun |
That distinction matters because the two have completely different responses. The ethics portion is largely irreducible — it is the local-board minority meeting monthly, and no amount of sponsor attention changes a board's calendar. The contracting portion is negotiable, and it is where the recoverable time actually is.
A program that attributes the whole overrun to ethics review has given itself permission to stop looking, which is the more expensive error. The number in this table is the reason the recovery plan targets contracting rather than submissions.
It is asserted at build time. If a future edit made the weighted ethics median fit inside the planned window, the fact base would refuse to import — because the activation plan would then have no explanation for its overrun and something else in the model would be wrong.
4. What the Sponsor Can and Cannot Do
| Lever | Does it work? | Why |
|---|---|---|
| Submit a complete package first time | Real | ⚠ The single largest controllable factor. An incomplete submission is returned unreviewed and waits for the next meeting — which on a monthly board is a six-week penalty for a missing CV. |
| Use the central board where permitted | Real | Halves the median. Already applied to every site whose institution allows it. |
| Track submission deadlines per board | Real | Boards meet on fixed schedules with cut-offs. Missing a cut-off by a day costs a full cycle, and the calendar is public. |
| Ask the board to expedite | None | ⚠ A sponsor has no standing to request priority, and asking damages the relationship the site depends on. |
| Escalate through the CRO | None | The CRO has no more standing than the sponsor. Meridian can chase administrative status; it cannot influence a review. |
| Negotiate the review outcome | None | ⚠ Improper. The board's independence is the protection for participants, and a sponsor attempting to influence it is a serious finding in its own right. |
Asking a board to expedite has no standing and damages the relationship the site depends on. Escalating through the CRO adds a party with no more standing than the sponsor. And attempting to influence a review outcome is a serious finding in its own right — the board's independence is the participant protection, and a sponsor working around it has undermined the thing the trial depends on for its legitimacy.
Listing the levers that do not work is more useful than listing only the ones that do, because under schedule pressure somebody will propose each of them, and the answer needs to be ready before the pressure arrives.
The one lever that carries most of the value is the dullest: submit a complete package the first time. An incomplete submission is returned unreviewed and waits for the next meeting, which on a monthly board turns a missing curriculum vitae into a six-week loss. The regulatory document package — Form FDA 1572, curricula vitae, medical licenses, financial disclosure — is collected at week 8 of the activation sequence precisely so that the week 9 submission is complete.
5. What Puts the Study Back in Front of the Board
| Trigger | Requirement | Consequence |
|---|---|---|
| Protocol amendment | Prior approval required | No participant may be enrolled or treated under the amended protocol until approved. ⚠ Except a change eliminating an immediate hazard, which is implemented first and reported after. |
| Informed consent form revision | Prior approval required | Includes any change to the risk section. Already-enrolled participants may require re-consent. |
| Continuing review | At least annually | ⚠ Approval EXPIRES. A site whose continuing review lapses must stop enrolling and, in some cases, stop dosing — a self-inflicted enrolment loss that is entirely preventable. |
| Safety report affecting risk | Prompt notification | Unanticipated problems involving risk to participants go to the board as well as to the agency. |
| Recruitment material | Prior approval required | Every advertisement, letter and screening script. Frequently forgotten, and it stops recruitment when it is. |
| Site closure | Notification | The board is told, and enrolled participants continue to be followed. |
An ethics approval is not permanent. It is granted for a period — typically a year — and a site whose continuing review lapses must stop enrolling immediately, and in some circumstances stop dosing. That is an entirely self-inflicted enrolment loss, caused by a calendar nobody watched, on a study that was otherwise proceeding normally.
With 231 sites active, each on its own approval anniversary, this is a tracking problem before it is anything else. It is managed in the same register as the approvals themselves, and a lapse is treated as an issue rather than an administrative slip.
Recruitment material is the second most commonly missed. Every advertisement, letter, and screening telephone script requires prior approval, and a site that produces its own local flyer in good faith has created a deviation. The rule sounds bureaucratic until you consider what it protects against: a study advertisement is the first thing a potential participant reads, and it is the easiest place in the entire trial to overstate a benefit.
6. Informed Consent
Three versions are in force across the program.
| Version | Approved at | What changed, and who re-consents |
|---|---|---|
| v1.0 | G4 | Original, approved at Phase 3 start. |
| v1.1 | G4 | Administrative — site contact details corrected. No re-consent. |
| v2.0 | G4 | ⚠ Cardiovascular sub-study added under CR-02. Re-consent required for participants electing to join; a new consent for those enrolling after. |
| Principle | What it means in practice |
|---|---|
| Consent is a process, not a form | The signed document evidences a conversation. An inspector interviews the coordinator about how consent was obtained, not only whether a signature exists. |
| It must precede any study procedure | ⚠ Including screening. A screening blood draw taken before the consent signature is a protocol deviation and a reportable one. |
| Readability is a compliance requirement | Written for the population, not for the sponsor. Boards routinely return consents for reading level alone, and each return costs a review cycle. |
| Re-consent is triggered by new information | New risk information, or a substantive protocol change affecting participants. Administrative changes do not trigger it — over-triggering burdens sites and confuses participants. |
An inspector does not primarily examine signatures. They interview the coordinator about how consent was obtained — whether the participant had time, whether questions were answered, whether anyone was consented by someone not delegated to do it. A file of perfectly executed forms does not survive an interview that reveals the conversations were rushed.
The most common serious finding in this area is timing: a screening procedure performed before the consent signature. It is usually a blood draw, usually done by someone being helpful, and it is a reportable deviation every time.
Version 2.0 is the interesting one. The cardiovascular sub-study added by change request CR-02 required a consent revision and re-consent for participants electing to join — a scope change reaching all the way down into a conversation with each individual participant, months after they first agreed to take part. That is the true cost of a mid-study scope addition, and it appears in no budget line.
7. The Approvals Record
Zone 4 of the Trial Master File holds one approval package per site — the largest single document count in the file — and it is what evidences that no participant was enrolled anywhere before the board said so.
| Held for every site | Why an inspector wants it |
|---|---|
| Initial approval letter, dated | ⚠ Compared against the date of the first participant's consent. The order of those two dates is the single most consequential thing in the zone. |
| The approved protocol version and consent version | Confirms the site was working from what the board approved, not a later draft. |
| Board membership or assurance number | Evidences the board itself is properly constituted and registered. |
| Every continuing review approval | Demonstrates unbroken coverage. A gap between one approval expiring and the next being granted is visible as a date range with nothing in it. |
| Approval of every amendment and consent revision | Each one dated before the amended protocol was used at that site. |
Approval before first consent. Consent before first procedure. Amendment approval before amended procedures. Continuing review before the prior one expired. The content of the documents is rarely the finding; the sequence of them almost always is.
Which makes this the zone where contemporaneous filing matters most, and where a file assembled retrospectively fails most visibly — because the one thing a reconstructed file cannot convincingly reproduce is a chain of dates that were always in the right order.
The ethics record outlives the program by the full 25-year retention period. Long after the last participant is followed up and the program is closed, this zone remains the evidence that 2,480 people agreed to take part in something that had been independently judged reasonable to ask of them.